Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Enzyme induction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Enzyme induction. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-001163-30 Sponsor Protocol Number: ALID02307 Start Date*: 2015-05-11
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase)
    Medical condition: Mucopolysaccharidosis I
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10056886 Mucopolysaccharidosis I PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003180-31 Sponsor Protocol Number: MC-ASP.5/ALL Start Date*: 2008-07-29
    Sponsor Name:medac GmbH
    Full Title: Comparative efficacy and safety of two asparaginase preparations in children with previously untreated acute lymphoblastic leukaemia
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003031-35 Sponsor Protocol Number: R04049 Start Date*: 2015-11-20
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: A Single Centre Study Investigating the Safety and Efficacy of an Immune Modulation Regimen in Mitigating the Alloimmune Response to Intravenous Laronidase in Infants With Severe Mucopolysaccharido...
    Medical condition: Severe Mucopolysaccharidosis Type I (Hurler syndrome, MPS IH)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10028094 Mucopolysaccharidosis IH LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006451-52 Sponsor Protocol Number: 4474 Start Date*: 2009-01-27
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: An investigation of the association between vitamin K intake, vitamin K epoxide reductase subunit (VKORC1) genotype and anticoagulation response to warfarin
    Medical condition: Patients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043566 Thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001428-38 Sponsor Protocol Number: RRK2939 Start Date*: 2006-09-18
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy
    Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023776-52 Sponsor Protocol Number: Lisette-1 Start Date*: 2011-01-19
    Sponsor Name:
    Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000642-62 Sponsor Protocol Number: M14-675 Start Date*: 2019-06-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulc...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) LV (Completed) PT (Completed) FI (Completed) DE (Completed) GR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) CZ (Completed) LT (Completed) IE (Completed) BE (Completed) HU (Completed) ES (Completed) SK (Completed) PL (Completed) FR (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-000211-25 Sponsor Protocol Number: MV-CHIK-205 Start Date*: 2018-07-27
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers
    Medical condition: The study is being conducted in healthy volunteers for the prophylaxis of chikungunya virus (CHIKV) infection.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000583-34 Sponsor Protocol Number: AGLU03707_MSC12817 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients with Pompe Disease Who Have Previously Received Myozyme
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000889-29 Sponsor Protocol Number: CLNP023X2202 Start Date*: 2018-12-13
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy
    Medical condition: C3 glomerulopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000942-77 Sponsor Protocol Number: EFC14028 Start Date*: 2016-07-15
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase ...
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036143 Pompe's disease LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) SE (Prematurely Ended) NL (Completed) ES (Completed) CZ (Completed) DE (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed) PT (Completed) BG (Completed) HU (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000690-36 Sponsor Protocol Number: TED14856 Start Date*: 2018-12-17
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020613-91 Sponsor Protocol Number: MC-PEGASP.1/adults Start Date*: 2010-11-18
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: A randomized, multi-centre, parallel-group, open label, Oncaspar® controlled dose ranging trial of three doses of pegylated recombinant asparaginase in adult patients with newly diagnosed acute lym...
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003517-17 Sponsor Protocol Number: ALL2518 Start Date*: 2019-09-26
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001522-84 Sponsor Protocol Number: V72P6 Start Date*: 2006-08-29
    Sponsor Name:Novartis Vaccines and Diagnostics Srl.
    Full Title: A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Health...
    Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020953-14 Sponsor Protocol Number: PosaBupreversion1.0 Start Date*: 2010-08-12
    Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital
    Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.
    Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000567-26 Sponsor Protocol Number: CKS/IND-CX/05 Start Date*: 2007-07-27
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA`
    Full Title: Phase II Trial for the Treatment of Advanced Classical Kaposi’s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy
    Medical condition: patients with advanced Kaposi sarcoma, stage III/IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023287 Kaposi's sarcoma classical LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001889-13 Sponsor Protocol Number: P04249 Start Date*: 2005-11-24
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.
    Medical condition: Adult subjects with a diagnosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximab
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Completed) GR (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005830-14 Sponsor Protocol Number: CVAY736K12301 Start Date*: 2022-07-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patien...
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) EE (Trial now transitioned) LT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:14:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA